April 23 (Reuters) – Novo Nordisk’s oral GLP-1 drug met the main goal of a late-stage study in children and adolescents aged 10 to 17 years with type 2 diabetes, the drugmaker said on Thursday.
The Danish drugmaker tested the pill in 132 patients aged 10 to 17 over a 26‑week period.
The study showed that patients taking the drug lowered their average blood sugar levels by 0.83 percentage points more than those given a placebo, a difference the company said was “statistically significant”.
Novo Nordisk said it plans to apply in the second half of 2026 for regulatory approval to expand the label for its oral semaglutide drugs, Ozempic pill and Rybelsus, in the United States and the European Union.
(Reporting by Mariam Sunny and Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila and Devika Syamnath)
